Chris Torrance

Chris Torrance is a prominent figure in the biotechnology industry, known for his roles as a cancer researcher, entrepreneur, and founder of multiple companies. He is currently the Founder and Chair of PhoreMost Ltd, a company he co-founded in 2014.13

Professional Background

Dr. Torrance has a strong background in cancer research and has leveraged this expertise to establish innovative biotechnology companies. Some key aspects of his career include:

• Co-founder of PhoreMost: In 2014, Torrance co-founded PhoreMost Ltd along with Professor Ashok Venkitaraman and Dr. Grahame Mckenzie.1 The company was spun out from the University of Cambridge's MRC Cancer Unit.

• Founder of Horizon Discovery: In 2007, Torrance founded Horizon Discovery, a company focused on advancing human genome editing.4

PhoreMost Ltd

PhoreMost, under Torrance's leadership, has developed cutting-edge technology in drug discovery:

• SITESEEKER® Platform: This next-generation phenotypic screening platform can identify new therapeutic targets and determine how to drug them effectively.1

• PROTEINi® Technology: The core proprietary technology that powers SITESEEKER, enabling the systematic unmasking of druggable sites across the human proteome.1

Current Role

As Founder and Chair of PhoreMost Ltd, Torrance continues to drive innovation in drug discovery and development. His LinkedIn profile indicates that he is based in the Greater Cambridge Area and has over 500 connections on the platform.2

Chris Torrance's work at PhoreMost and his previous ventures demonstrate his commitment to advancing cancer research and developing novel therapeutic approaches for diseases with unmet needs.